Chelsea Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chelsea Anderson has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Hazel B. Nichols
Department of Epidemiology, Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
35 shared publications Hazel B. Nichols
Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
22 shared publications- Dale P. Sandler
Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, Durham, NC, USA
14 shared publications - Andrew F. Olshan
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
11 shared publications Melissa House
11 shared publications- Jennifer L. Lund
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
10 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (9)
Symptom burden is associated with health-related quality of life in symptomatic adults with primary sclerosing cholangitis
Background: The Primary Sclerosing Cholangitis Symptom Assessment Project (PSC-SAP) is a research initiative aimed at developing regulatory-grade PSC-specific symptom measures. During the initial screening phase for PSC-SAP, patient-reported symptom data were collected from a cohort of symptomatic adults. The current study aims to comprehensively characterize a range of symptoms and identify predictors of symptom burden and mental and physical health-related quality of life (HRQOL). Methods: Adults were primarily recruited through the PSC Partners Patient Registry for this cross-sectional study. Eligible participants completed a telephone-based survey that screened for 13 PSC-associated symptoms experienced in the last month and collected sociodemographic, clinical, and HRQOL scores using the PROMIS (Patient-Reported Outcomes Measurement Information System) global health measure. Multivariable linear regressions were used to model outcomes of total symptom burden and HRQOL. Results: Among 126 symptomatic participants, 88% were White, 60% were female, and the mean age was 47 years. The most prevalent symptoms were fatigue (83%) and daytime drowsiness (73%), followed by >60% reporting anxiety, liver pain, brain fog, sleep disturbance, and pruritus. Female sex and cirrhosis were associated with higher symptom burden scores. Factors such as age, history of cholangitis attacks, and inflammatory bowel disease (IBD) were not. Adding a total symptom burden score to initial models substantially increased the explanation of variation in mental HRQOL (from 9% to 48%) and physical HRQOL (from 12% to 51%) scores. Conclusions: Among symptomatic adults living with PSC, 6 PSC symptoms emerged as highly prevalent. With total symptom burden strongly associated with mental and physical HRQOL, multisymptom assessments should be utilized in future HRQOL studies of PSC and may help improve clinical care for those suffering from PSC.
- 20 August 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (9)
Open AccessSymptom burden is associated with health-related quality of life in symptomatic adults with primary sclerosing cholangitis
Background: The Primary Sclerosing Cholangitis Symptom Assessment Project (PSC-SAP) is a research initiative aimed at developing regulatory-grade PSC-specific symptom measures. During the initial screening phase for PSC-SAP, patient-reported symptom data were collected from a cohort of symptomatic adults. The current study aims to comprehensively characterize a range of symptoms and identify predictors of symptom burden and mental and physical health-related quality of life (HRQOL). Methods: Adults were primarily recruited through the PSC Partners Patient Registry for this cross-sectional study. Eligible participants completed a telephone-based survey that screened for 13 PSC-associated symptoms experienced in the last month and collected sociodemographic, clinical, and HRQOL scores using the PROMIS (Patient-Reported Outcomes Measurement Information System) global health measure. Multivariable linear regressions were used to model outcomes of total symptom burden and HRQOL. Results: Among 126 symptomatic participants, 88% were White, 60% were female, and the mean age was 47 years. The most prevalent symptoms were fatigue (83%) and daytime drowsiness (73%), followed by >60% reporting anxiety, liver pain, brain fog, sleep disturbance, and pruritus. Female sex and cirrhosis were associated with higher symptom burden scores. Factors such as age, history of cholangitis attacks, and inflammatory bowel disease (IBD) were not. Adding a total symptom burden score to initial models substantially increased the explanation of variation in mental HRQOL (from 9% to 48%) and physical HRQOL (from 12% to 51%) scores. Conclusions: Among symptomatic adults living with PSC, 6 PSC symptoms emerged as highly prevalent. With total symptom burden strongly associated with mental and physical HRQOL, multisymptom assessments should be utilized in future HRQOL studies of PSC and may help improve clinical care for those suffering from PSC.
- 27 July 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Behavioral alcohol use disorder therapy in early liver transplant evaluation for alcohol-associated liver disease – a multicenter retrospective cohort study
Background: Behavioral alcohol use disorder therapy (bAUDT) is increasingly used to improve eligibility and outcomes for liver transplant (LT) among patients with alcohol-associated liver disease (ALD), especially as more centers consider LT for patients with Methods: RESOLVE-ALD is a multicenter retrospective cohort study including adults with ALD and Results: Among 545 patients analyzed (median sobriety time 79 days; 52.8% inpatient evaluations), 22.4% participated in bAUDT during LTE and 43% received LT. Prior alcohol-related illness (aOR=1.93, p =0.03) and heavier daily drinking (aOR=1.90, p =0.04) were associated with increased adjusted odds of bAUDT during LTE, while older age (aOR=0.41, p =0.006), underinsurance (aOR=0.42, p =0.01), and hospitalization during LTE (aOR=0.42, p =0.02) were associated with reduced adjusted odds. bAUDT participation during LTE significantly increased adjusted odds of LT waitlisting (aOR=3.40, p =0.006), but did not predict return to use pre- or post-LT. Conclusion: bAUDT is more common among patients with risk factors for return to use and with the medical and financial stability to participate in therapy. Although associated with increased waitlisting adjusted odds, bAUDT does not significantly predict return to alcohol use pre- or post-LT. Future research should explore optimal methods of integrating bAUDT into the LTE process to improve access and minimize barriers to LT.
- 27 July 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Behavioral alcohol use disorder therapy in early liver transplant evaluation for alcohol-associated liver disease – a multicenter retrospective cohort study
Background: Behavioral alcohol use disorder therapy (bAUDT) is increasingly used to improve eligibility and outcomes for liver transplant (LT) among patients with alcohol-associated liver disease (ALD), especially as more centers consider LT for patients with Methods: RESOLVE-ALD is a multicenter retrospective cohort study including adults with ALD and Results: Among 545 patients analyzed (median sobriety time 79 days; 52.8% inpatient evaluations), 22.4% participated in bAUDT during LTE and 43% received LT. Prior alcohol-related illness (aOR=1.93, p =0.03) and heavier daily drinking (aOR=1.90, p =0.04) were associated with increased adjusted odds of bAUDT during LTE, while older age (aOR=0.41, p =0.006), underinsurance (aOR=0.42, p =0.01), and hospitalization during LTE (aOR=0.42, p =0.02) were associated with reduced adjusted odds. bAUDT participation during LTE significantly increased adjusted odds of LT waitlisting (aOR=3.40, p =0.006), but did not predict return to use pre- or post-LT. Conclusion: bAUDT is more common among patients with risk factors for return to use and with the medical and financial stability to participate in therapy. Although associated with increased waitlisting adjusted odds, bAUDT does not significantly predict return to alcohol use pre- or post-LT. Future research should explore optimal methods of integrating bAUDT into the LTE process to improve access and minimize barriers to LT.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Background:Endometrial cancer and its treatment may impact urinary system function, but few large-scale studies have examined urinary diagnoses among endometrial cancer survivors. We investigated the risk of several urinary outcomes among older women with endometrial cancer compared with similar women without a cancer history.Methods:Women aged 66+ years with an endometrial cancer diagnosis during 2004–2017 (N = 44,386) and women without a cancer history (N = 221,219) matched 1:5 on exact age, race/ethnicity, and state were identified in the Surveillance, Epidemiology, and End Results-Medicare linked data. ICD-9 and -10 diagnosis codes were used to define urinary outcomes in the Medicare claims. HRs for urinary outcomes were estimated using multivariable Cox proportional hazards regression models.Results:Relative to women without cancer, endometrial cancer survivors were at an increased risk of several urinary system diagnoses, including lower urinary tract infection [HR, 2.36; 95% confidence interval (CI), 2.32–2.40], urinary calculus (HR, 2.22; 95% CI, 2.13–2.31), renal failure (HR, 2.28; 95% CI, 2.23–2.33), and chronic kidney disease (HR, 1.85; 95% CI, 1.81–1.90). Similar associations were observed in sensitivity analyses limited to 1+ and 5+ years after endometrial cancer diagnosis. Black race, higher comorbidity index, higher stage or grade cancer, non-endometrioid histology, and treatment with chemotherapy and/or radiation were often significant predictors of urinary outcomes among endometrial cancer survivors.Conclusions:Our results suggest that, among older women, the risk of urinary outcomes is elevated after endometrial cancer.Impact:Monitoring for urinary diseases may be a critical part of long-term survivorship care for older women with an endometrial cancer history.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Background:Endometrial cancer and its treatment may impact urinary system function, but few large-scale studies have examined urinary diagnoses among endometrial cancer survivors. We investigated the risk of several urinary outcomes among older women with endometrial cancer compared with similar women without a cancer history.Methods:Women aged 66+ years with an endometrial cancer diagnosis during 2004–2017 (N = 44,386) and women without a cancer history (N = 221,219) matched 1:5 on exact age, race/ethnicity, and state were identified in the Surveillance, Epidemiology, and End Results-Medicare linked data. ICD-9 and -10 diagnosis codes were used to define urinary outcomes in the Medicare claims. HRs for urinary outcomes were estimated using multivariable Cox proportional hazards regression models.Results:Relative to women without cancer, endometrial cancer survivors were at an increased risk of several urinary system diagnoses, including lower urinary tract infection [HR, 2.36; 95% confidence interval (CI), 2.32–2.40], urinary calculus (HR, 2.22; 95% CI, 2.13–2.31), renal failure (HR, 2.28; 95% CI, 2.23–2.33), and chronic kidney disease (HR, 1.85; 95% CI, 1.81–1.90). Similar associations were observed in sensitivity analyses limited to 1+ and 5+ years after endometrial cancer diagnosis. Black race, higher comorbidity index, higher stage or grade cancer, non-endometrioid histology, and treatment with chemotherapy and/or radiation were often significant predictors of urinary outcomes among endometrial cancer survivors.Conclusions:Our results suggest that, among older women, the risk of urinary outcomes is elevated after endometrial cancer.Impact:Monitoring for urinary diseases may be a critical part of long-term survivorship care for older women with an endometrial cancer history.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
Supplementary Table from Adverse Urinary System Diagnoses among Older Women with Endometrial Cancer
- 6 August 2025
- Published by Wolters Kluwer Health in Medical Care
Claims-Based Measures of Care Coordination and Long-Term Health Among Older Women With Endometrial Cancer
Background: Coordination of care between providers may help ensure that cancer survivors receive the appropriate health care services to improve their long-term health. We examined associations between a claims-based measure of care coordination and several health outcomes among older endometrial cancer survivors. Methods: Using SEER-Medicare data, we identified women with endometrial cancer at ages 66+ during 2009–2015 (N=13,696). Medicare claims during years 1–3 postdiagnosis were used to calculate care density, a measure of care coordination, as the ratio of the number of patients shared among a woman’s outpatient providers to the number of provider pairs seen by that patient. We estimated associations between care density tertile and hospitalizations, emergency room (ER) visits, and all-cause mortality from 3 years postdiagnosis on, and adherence to guideline-recommended follow-up during years 3–5 postdiagnosis. Results: No clear trends were observed for risk of all-cause mortality, hospitalizations or ER visits according to care density category. However, for hospitalizations (HR=0.93; 95% CI: 0.87–0.99) and ER visits (HR=0.93; 95% CI: 0.88–0.98), there was a slightly lower risk in the highest care density tertile compared with the lowest. Women in the middle (OR=1.67; 95% CI: 1.40–2.00) and highest care density tertiles (OR=1.63; 95% CI: 1.36–1.96) were more likely to be adherent to follow-up recommendations than those in the lowest tertile. Conclusions: Greater care coordination during the early survivorship period may be associated with a slightly lower risk of hospitalization and ER visits and better adherence to surveillance recommendations after endometrial cancer.
- 6 August 2025
- Published by Wolters Kluwer Health in Medical Care
Claims-Based Measures of Care Coordination and Long-Term Health Among Older Women With Endometrial Cancer
Background: Coordination of care between providers may help ensure that cancer survivors receive the appropriate health care services to improve their long-term health. We examined associations between a claims-based measure of care coordination and several health outcomes among older endometrial cancer survivors. Methods: Using SEER-Medicare data, we identified women with endometrial cancer at ages 66+ during 2009–2015 (N=13,696). Medicare claims during years 1–3 postdiagnosis were used to calculate care density, a measure of care coordination, as the ratio of the number of patients shared among a woman’s outpatient providers to the number of provider pairs seen by that patient. We estimated associations between care density tertile and hospitalizations, emergency room (ER) visits, and all-cause mortality from 3 years postdiagnosis on, and adherence to guideline-recommended follow-up during years 3–5 postdiagnosis. Results: No clear trends were observed for risk of all-cause mortality, hospitalizations or ER visits according to care density category. However, for hospitalizations (HR=0.93; 95% CI: 0.87–0.99) and ER visits (HR=0.93; 95% CI: 0.88–0.98), there was a slightly lower risk in the highest care density tertile compared with the lowest. Women in the middle (OR=1.67; 95% CI: 1.40–2.00) and highest care density tertiles (OR=1.63; 95% CI: 1.36–1.96) were more likely to be adherent to follow-up recommendations than those in the lowest tertile. Conclusions: Greater care coordination during the early survivorship period may be associated with a slightly lower risk of hospitalization and ER visits and better adherence to surveillance recommendations after endometrial cancer.
- 25 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1165-1172
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch
INTRODUCTION: Many patients with chronic pouchitis and Crohn's-like disease of the pouch (CLDP) are treated with biologics; however, the comparative effectiveness of advanced therapies in this population has not been systematically evaluated. We sought to compare the effectiveness of antitumor necrosis factor α (anti-TNF) therapies and ustekinumab in patients with chronic inflammatory conditions of the pouch. METHODS: We conducted a prospective, multicenter, cohort study. We included patients with chronic pouchitis and CLDP initiating treatment with anti-TNF therapies or ustekinumab. The primary outcome was clinical remission at 6 months after induction. We also evaluated clinical remission at 6 months among patients with chronic pouchitis and CLDP separately. RESULTS: Among 132 patients, 106 (80%) had a diagnosis of CLDP and 82 (62%) initiated therapy with ustekinumab. A significantly higher proportion of patients with CLDP treated with ustekinumab were in clinical remission at 6 months as compared with patients treated with anti-TNF therapy (62% vs 40%, P = 0.027); however, there was no significant difference among patients with chronic pouchitis ( P = 0.946). There was no independent statistical significance in the odds of remission at 6 months among patients with CLDP among patients receiving ustekinumab compared with anti-TNF therapy (adjusted odds ratio 1.91, 95% confidence interval 0.69–5.30) after adjusting for presence of a fistula, number of preoperative advanced therapies, and number of advanced therapies after IPAA. DISCUSSION: These data suggest the potential benefit of ustekinumab in patients with CLDP and should prompt future novel effectiveness evaluations in this population.
- 25 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1165-1172
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch
INTRODUCTION: Many patients with chronic pouchitis and Crohn's-like disease of the pouch (CLDP) are treated with biologics; however, the comparative effectiveness of advanced therapies in this population has not been systematically evaluated. We sought to compare the effectiveness of antitumor necrosis factor α (anti-TNF) therapies and ustekinumab in patients with chronic inflammatory conditions of the pouch. METHODS: We conducted a prospective, multicenter, cohort study. We included patients with chronic pouchitis and CLDP initiating treatment with anti-TNF therapies or ustekinumab. The primary outcome was clinical remission at 6 months after induction. We also evaluated clinical remission at 6 months among patients with chronic pouchitis and CLDP separately. RESULTS: Among 132 patients, 106 (80%) had a diagnosis of CLDP and 82 (62%) initiated therapy with ustekinumab. A significantly higher proportion of patients with CLDP treated with ustekinumab were in clinical remission at 6 months as compared with patients treated with anti-TNF therapy (62% vs 40%, P = 0.027); however, there was no significant difference among patients with chronic pouchitis ( P = 0.946). There was no independent statistical significance in the odds of remission at 6 months among patients with CLDP among patients receiving ustekinumab compared with anti-TNF therapy (adjusted odds ratio 1.91, 95% confidence interval 0.69–5.30) after adjusting for presence of a fistula, number of preoperative advanced therapies, and number of advanced therapies after IPAA. DISCUSSION: These data suggest the potential benefit of ustekinumab in patients with CLDP and should prompt future novel effectiveness evaluations in this population.
- Open Access
- 10 June 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (4)
Fertility preservation and in vitro fertilization (IVF) success rates after cancer
Background: Evidence of the success of in vitro fertilization (IVF) procedures is critical for informed decision making before and after cancer treatment. We compared IVF outcomes between women with and without cancer. Methods: Using data from a national IVF database—the Society for Assisted Reproductive Clinic Outcomes Reporting System, linked to statewide cancer registries and birth certificates in 9 states—we identified women who initiated IVF after a cancer diagnosis. Fertility preservation was defined as oocyte retrieval ≤90 days after cancer diagnosis, and IVF after cancer treatment as retrieval >90 days postdiagnosis. Number of oocytes retrieved and conception and livebirth rates were compared between these groups and a comparison group of women without cancer in couples with male factor infertility only. Results: Compared with retrievals for male factor infertility only (n = 81 370), the number of oocytes retrieved was not significantly different for women who underwent retrieval for fertility preservation (n = 2941) but was significantly lower for women who underwent retrievals after cancer treatment (n = 2479) (mean difference = −2.99, 95% confidence interval [CI] = −3.40 to 2.59). Rate of conception as a function of transfer attempts and likelihood of livebirth after conception also did not significantly differ for fertility preservation (n = 291) compared with male factor infertility only (n = 34 410). Women with IVF after cancer treatment (n = 672) had a lower rate of conception (hazard ratio = 0.70, 95% CI = 0.61 to 0.79) but a similar overall likelihood of a livebirth after conception, relative to the group with male factor infertility only. Conclusion: IVF outcomes may be maximized when ovarian retrieval is initiated before cancer treatment.
- 10 June 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (4)
Open AccessFertility preservation and in vitro fertilization (IVF) success rates after cancer
Background: Evidence of the success of in vitro fertilization (IVF) procedures is critical for informed decision making before and after cancer treatment. We compared IVF outcomes between women with and without cancer. Methods: Using data from a national IVF database—the Society for Assisted Reproductive Clinic Outcomes Reporting System, linked to statewide cancer registries and birth certificates in 9 states—we identified women who initiated IVF after a cancer diagnosis. Fertility preservation was defined as oocyte retrieval ≤90 days after cancer diagnosis, and IVF after cancer treatment as retrieval >90 days postdiagnosis. Number of oocytes retrieved and conception and livebirth rates were compared between these groups and a comparison group of women without cancer in couples with male factor infertility only. Results: Compared with retrievals for male factor infertility only (n = 81 370), the number of oocytes retrieved was not significantly different for women who underwent retrieval for fertility preservation (n = 2941) but was significantly lower for women who underwent retrievals after cancer treatment (n = 2479) (mean difference = −2.99, 95% confidence interval [CI] = −3.40 to 2.59). Rate of conception as a function of transfer attempts and likelihood of livebirth after conception also did not significantly differ for fertility preservation (n = 291) compared with male factor infertility only (n = 34 410). Women with IVF after cancer treatment (n = 672) had a lower rate of conception (hazard ratio = 0.70, 95% CI = 0.61 to 0.79) but a similar overall likelihood of a livebirth after conception, relative to the group with male factor infertility only. Conclusion: IVF outcomes may be maximized when ovarian retrieval is initiated before cancer treatment.